Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients

Inclusion Criteria: * Histologically proven cancer of the prostate, based on prostate biopsy-core analysis. * At least one 18F/68Ga-PSMA-PET/CT suspected positive metastasis in lymph nodes, located in the pelvic region. * Patient is scheduled and fit for robot assisted surgery (PLND or radical prostatectomy +PLND). * Patient is suitable for PLND (and radical prostatectomy) conform institutional guidelines and is not yet treated pre-operatively . * Age≥50 years. * Ability to give voluntary written informed consent to participate in this study. Exclusion Criteria: * No detectable lesion on the 18F/68Ga-PSMA-PET/CT with an uptake level above liver uptake level (reference). * Patients who are not scheduled for robot-assisted PLND. * Prior pelvic surgery(1) * Unequivocal evidence of metastases outside the pelvic region. * Presence of any medical condition that in the opinion of the investigator/treating physician will affect patients' clinical status by participating in this trial. * Prior prostate cancer treatment(2). * Contraindication for MRI-scanning, i.e. claustrophobia, intracranial metal clips, metallic bodies in the eye, implanted electric and electronic devices not eligible for MRI (pacemakers, insulin pumps, cochlear implants, neurostimulators). * Inability to lie still for at least 60 minutes or comply with imaging. * Contraindication for iron infusion or hypersensitivity/allergy to the active substance or any of the excipients. * The patient is already enrolled in one or more concurrent studies, which could confound the results of this study, according to the investigators. 1. Pelvic surgery is defined as "any surgery associated with pelvic lymphadenopathy'. 2. Prior prostate cancer treatment is defined as prostate and/or pelvic radiotherapy, hormonal treatments such as androgen deprivation therapy, prostate brachytherapy, prostate cryotherapy, high intensity focused ultrasound (HIFU) and/or prostate electroporation.